RNTX CIK: 1420565

Rein Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
48.2
FY22:
21.9
FY23:
18.3
FY24:
13.7
FY25:
4.33
(positive)
Change from FY21 to FY25
millions USD
FY21:
0.30
FY22:
0.13
FY23:
87.7
FY24:
48.5
FY25:
19.8
Total assets
Change from FY21 to FY25
millions USD
FY21:
48.5
FY22:
22.0
FY23:
106
FY24:
62.2
FY25:
24.2

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
4.51
FY22:
3.38
FY23:
4.39
FY24:
5.75
FY25:
6.18
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.07
FY22:
0
FY23:
3.33
FY24:
2.05
FY25:
1.06
(positive)
Change from FY21 to FY25
millions USD
FY21:
43.9
FY22:
18.6
FY23:
98.3
FY24:
54.4
FY25:
16.9
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
48.5
FY22:
22.0
FY23:
106
FY24:
62.2
FY25:
24.2

All amounts in millions USD Data source:SEC EDGAR